{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T06:32:10Z","timestamp":1776580330700,"version":"3.51.2"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"crossref","award":["72174110"],"award-info":[{"award-number":["72174110"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aimed to describe current treatments for haemophilia A in China, focusing on their associated clinical, humanistic, and economic burdens in a real-world context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cross-sectional study. We investigated the demographics, disease severity, treatment strategies, and clinical outcomes of patients diagnosed with haemophilia A. We also investigated the cost of the treatment of patients with haemophilia A. In the real world, we estimated annual direct medical costs, direct non-medical costs and indirect costs. In addition, we employed the EQ-5D and SF-6D to measure the humanistic burden of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 60 patients were included in the study, comprising 22 children (&lt;\u200918 years) and 38 adults (\u2265\u200918 years). The mean age of the children and adults was 9.27 and 33.05 years, respectively. Treatment strategies for adults were primarily on-demand. Patients receiving prophylactic treatment experienced fewer bleeds per year compared to those receiving on-demand treatment (mean ABR: adults 42.91 vs. 20.38; children 20.20 vs. 10.10). The mean EQ-5D utility value reported by children and adults were 0.76 (SD 0.24) and 0.51 (SD 0.34), respectively. For adult patients, the SF-6D utility value was 0.38. The mean total annual direct medical costs associated with haemophilia were \u00a5429,143 (US$58,666) for children and \u00a5340,238 (US$46,512) for adults, with medication being the primary cost driver.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data document the enormous burden of haemophilia A that persists in the real world of China. While we emphasize incremental direct healthcare expenditures, we must also consider the long-term clinical and socio-economic benefits of prophylactic treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04051-1","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:39:10Z","timestamp":1761298750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical, humanistic, and economic burden of haemophilia A in China: findings from a real-world survey"],"prefix":"10.1186","volume":"20","author":[{"given":"Junchao","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8457-0224","authenticated-orcid":false,"given":"Lei","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingdan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunhai","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"4051_CR1","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of Hemophilia, 3rd edn. Haemophilia. 2020;26 Suppl 6:1\u2013158.","DOI":"10.1111\/hae.14046"},{"key":"4051_CR2","first-page":"89","volume":"22","author":"F Xue","year":"2023","unstructured":"Xue F, Dai J, Chen L, Liu W, Zhang H, Wu R, et al. Report on diagnosis and treatment of hemophilia in China 2023. J Diagnostics Concepts Pract. 2023;22:89\u2013115.","journal-title":"J Diagnostics Concepts Pract"},{"key":"4051_CR3","first-page":"461","volume":"13","author":"China National Haemophilia Cooperative Group","year":"1992","unstructured":"China National Haemophilia Cooperative Group. A survey on the prevalence of haemophilia in China and survival rates in eight regions. Chin J Hematol. 1992;13:461\u20133.","journal-title":"Chin J Hematol"},{"key":"4051_CR4","first-page":"65","volume":"35","author":"Y QU","year":"2014","unstructured":"QU Y, Nie X, Yang Z, Zhan S. Meta analysis of the prevalence of hemophilia in Mainland China. Chin J Hematol. 2014;35:65\u20138.","journal-title":"Chin J Hematol"},{"key":"4051_CR5","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/hae.14029","volume":"26","author":"X Song","year":"2020","unstructured":"Song X, Liu W, Xue F, Zhong J, Yang Y, Liu Y, et al. Real-world analysis of haemophilia patients in china: A single centre\u2019s experience. Haemophilia. 2020;26:584\u201390.","journal-title":"Haemophilia"},{"key":"4051_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","volume":"19","author":"A Srivastava","year":"2013","unstructured":"Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1\u201347.","journal-title":"Haemophilia"},{"key":"4051_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1750-1172-7-24","volume":"7","author":"M Franchini","year":"2012","unstructured":"Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis. 2012;7:24.","journal-title":"Orphanet J Rare Dis"},{"key":"4051_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","volume":"388","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388:187\u201397.","journal-title":"Lancet"},{"key":"4051_CR9","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/hae.13762","volume":"25","author":"M Carcao","year":"2019","unstructured":"Carcao M, Escuriola-Ettingshausen C, Santagostino E, Oldenburg J, Liesner R, Nolan B, et al. The changing face of immune tolerance induction in haemophilia A with the advent of Emicizumab. Haemophilia. 2019;25:676\u201384.","journal-title":"Haemophilia"},{"key":"4051_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14737167.2020.1789457","volume":"21","author":"HK Kim","year":"2021","unstructured":"Kim HK, Peral C, Rubio-Rodr\u00edguez D, Rubio-Terr\u00e9s C. Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain. Expert Rev Pharmacoecon Outcomes Res. 2021;21:315\u201320.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"4051_CR11","first-page":"370","volume":"1","author":"R Feng Xue","year":"2022","unstructured":"Feng Xue R. Establishment and evolution of China National hemophilia registry. J Rare Dis. 2022;1:370\u20134.","journal-title":"J Rare Dis"},{"key":"4051_CR12","unstructured":"National Health Commission of the People\u2019s Republic of China. Notice on the publication of the first list of rare diseases [Internet]. 2018 [cited 2021 Jan 3]. Available from: http:\/\/www.nhc.gov.cn\/yzygj\/s7659\/201806\/393a9a37f39c4b458d6e830f40a4bb99.shtml"},{"key":"4051_CR13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13023-023-02838-8","volume":"18","author":"Z Liu","year":"2023","unstructured":"Liu Z, Feng J, Fang Y, Cheng Y, Li S. Barriers to prophylactic treatment among patients with haemophilia A in Shandong Province, china: a qualitative study. Orphanet J Rare Dis. 2023;18:226.","journal-title":"Orphanet J Rare Dis"},{"key":"4051_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13023-023-02835-x","volume":"18","author":"L Zhang","year":"2023","unstructured":"Zhang L, Zhang P, Chen W. Treatment regimens, patient reported outcomes and health-related quality of life in children with moderate and severe hemophilia A in china: using real-world data. Orphanet J Rare Dis. 2023;18:232.","journal-title":"Orphanet J Rare Dis"},{"key":"4051_CR15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/hae.13498","volume":"24","author":"TM Dale","year":"2018","unstructured":"Dale TM, Saucedo JM, Rodriguez-Merchan EC. Total elbow arthroplasty in haemophilia. Haemophilia. 2018;24:548\u201356.","journal-title":"Haemophilia"},{"key":"4051_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/joim.12301","volume":"277","author":"M Osooli","year":"2015","unstructured":"Osooli M, Berntorp E. Inhibitors in haemophilia: what have we learned from registries? A systematic review. J Intern Med. 2015;277:1\u201315.","journal-title":"J Intern Med"},{"key":"4051_CR17","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12913-022-07626-x","volume":"22","author":"Z Huang","year":"2022","unstructured":"Huang Z, Nicholas S, Yang Y, Chen X, Maitland E, Ma Y, et al. Medical costs and hospital utilization for hemophilia A and B urban inpatients in China: a National cross-sectional study. BMC Health Serv Res. 2022;22:230.","journal-title":"BMC Health Serv Res"},{"key":"4051_CR18","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/hae.14615","volume":"28","author":"W Zhang","year":"2022","unstructured":"Zhang W, Xie S, Xue F, Liu W, Chen L, Zhang L, et al. Health-related quality of life among adults with haemophilia in china: A comparison with age\u2010matched general population. Haemophilia. 2022;28:776\u201383.","journal-title":"Haemophilia"},{"key":"4051_CR19","doi-asserted-by":"crossref","unstructured":"Guan T, Ai D, Zhao N, Liu G, Yao W, Chen Z, et al. Treatment-related outcome from patient report outcome (PRO) of children with severe and moderate hemophilia A in China: an analysis report of registration data from patient organization hemophilia home care center. Haemophilia. 2023;29:1467-1474","DOI":"10.1111\/hae.14863"},{"key":"4051_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13023-022-02300-1","volume":"17","author":"I Rodriguez-Santana","year":"2022","unstructured":"Rodriguez-Santana I, DasMahapatra P, Burke T, Hakimi Z, Bartelt-Hofer J, Nazir J, et al. Differential humanistic and economic burden of mild, moderate and severe haemophilia in European adults: a regression analysis of the CHESS II study. Orphanet J Rare Dis. 2022;17:148.","journal-title":"Orphanet J Rare Dis"},{"key":"4051_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1186\/s13023-021-02152-1","volume":"16","author":"T Burke","year":"2021","unstructured":"Burke T, Asghar S, O\u2019Hara J, Chuang M, Sawyer EK, Li N. Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe. Orphanet J Rare Dis. 2021;16:521.","journal-title":"Orphanet J Rare Dis"},{"key":"4051_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13023-021-01774-9","volume":"16","author":"T Burke","year":"2021","unstructured":"Burke T, Asghar S, O\u2019Hara J, Sawyer EK, Li N. Clinical, humanistic, and economic burden of severe hemophilia B in the united states: results from the CHESS US and CHESS US\u2009+\u2009population surveys. Orphanet J Rare Dis. 2021;16:143.","journal-title":"Orphanet J Rare Dis"},{"key":"4051_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13023-020-01423-7","volume":"15","author":"G Gong","year":"2020","unstructured":"Gong G, Chen Y, Fang P, Min R. Medical expenditure for patients with hemophilia in urban china: data from medical insurance information system from 2013 to 2015. Orphanet J Rare Dis. 2020;15:137.","journal-title":"Orphanet J Rare Dis"},{"key":"4051_CR24","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10198-021-01273-5","volume":"22","author":"RH Xu","year":"2021","unstructured":"Xu RH, Dong D, Luo N, Wong EL-Y, Wu Y, Yu S, et al. Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia. Eur J Health Econ. 2021;22:547\u201357.","journal-title":"Eur J Health Econ"},{"key":"4051_CR25","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/jth.12672","volume":"12","author":"VS Blanchette","year":"2014","unstructured":"Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12:1935\u20139.","journal-title":"J Thromb Haemost"},{"key":"4051_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/hae.14766","volume":"29","author":"P Chowdary","year":"2023","unstructured":"Chowdary P, Nissen F, Burke T, Aizenas M, Czirok T, Dhillon H, et al. The humanistic and economic burden of problem joints for children and adults with moderate or severe haemophilia A: analysis of the CHESS population studies. Haemophilia. 2023;29:753\u201360.","journal-title":"Haemophilia"},{"key":"4051_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/hae.13197","volume":"23","author":"PF Limperg","year":"2017","unstructured":"Limperg PF, Terwee CB, Young NL, Price VE, Gouw SC, Peters M, et al. Health-related quality of life questionnaires in individuals with haemophilia: a systematic review of their measurement properties. Haemophilia. 2017;23:497\u2013510.","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"4051_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10198-016-0785-2","volume":"17","author":"M Cavazza","year":"2016","unstructured":"Cavazza M, Kodra Y, Armeni P, De Santis M, L\u00f3pez-Bastida J, Linertov\u00e1 R, et al. Social\/economic costs and quality of life in patients with haemophilia in Europe. Eur J Health Econ. 2016;17(Suppl 1):53\u201365.","journal-title":"Eur J Health Econ"},{"key":"4051_CR29","doi-asserted-by":"publisher","first-page":"460","DOI":"10.2165\/00019053-199610050-00003","volume":"10","author":"MA Koopmanschap","year":"1996","unstructured":"Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. PharmacoEconomics. 1996;10:460\u20136.","journal-title":"PharmacoEconomics"},{"key":"4051_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13023-019-1175-5","volume":"14","author":"A Caf\u00e9","year":"2019","unstructured":"Caf\u00e9 A, Carvalho M, Crato M, Faria M, Kjollerstrom P, Oliveira C, et al. Haemophilia A: health and economic burden of a rare disease in Portugal. Orphanet J Rare Dis. 2019;14:211.","journal-title":"Orphanet J Rare Dis"},{"key":"4051_CR31","unstructured":"World Federation of Hemophilia. Report on the global annual survey [Internet]. 2019 [cited 2020 Nov 10]. Available from: https:\/\/www1.wfh.org\/publications\/files\/pdf-1731.pdf"},{"key":"4051_CR32","doi-asserted-by":"crossref","unstructured":"Manco-Johnson MJ, Soucie JM, Gill JC. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood. 2017;129:2368\u201374. Joint Outcomes Committee of the Universal Data Collection, US Hemophilia Treatment Center Network.","DOI":"10.1182\/blood-2016-02-683169"},{"key":"4051_CR33","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1111\/hae.14217","volume":"27","author":"X Song","year":"2021","unstructured":"Song X, Zhong J, Xue F, Chen L, Li H, Yuan D, et al. An overview of patients with haemophilia A in china: Epidemiology, disease severity and treatment strategies. Haemophilia. 2021;27:e51\u20139.","journal-title":"Haemophilia"},{"key":"4051_CR34","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/hae.13372","volume":"24","author":"Z Li","year":"2018","unstructured":"Li Z, Wu J, Zhao Y, Liu R, Li K, Zhou Y, et al. Influence of medical insurance schemes and charity assistance projects on regular prophylaxis treatment of the boys with severe haemophilia A in China. Haemophilia. 2018;24:126\u201333.","journal-title":"Haemophilia"},{"key":"4051_CR35","first-page":"485","volume":"36","author":"H Wang Xu","year":"2020","unstructured":"Wang Xu H, Xiaoning W, Jing. Effect of reimbursement policy of basic medical insurance on the treatment level and cost of hemophilia A patients in China-All databases. Chin J Hosp Adm. 2020;36:485\u20139.","journal-title":"Chin J Hosp Adm"},{"key":"4051_CR36","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1080\/03007995.2017.1310720","volume":"33","author":"C Li","year":"2017","unstructured":"Li C, Zhang X, Zhao Y, Wu R, Hu Q, Xu W, et al. Long-term efficacy and safety of prophylaxis with Recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study. Curr Med Res Opin. 2017;33:1223\u201330.","journal-title":"Curr Med Res Opin"},{"key":"4051_CR37","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1111\/hae.13751","volume":"25","author":"R Yang","year":"2019","unstructured":"Yang R, Sun J, Zhao Y, Wang X, Wu D, Tseneklidou-Stoeter D, et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia. 2019;25:e153\u20138.","journal-title":"Haemophilia"},{"key":"4051_CR38","unstructured":"Li, Changyin, Yin Yuru. Study on medical security mechanism of rare diseases:a case study of hemophilia. China Health Insurance. 2023;7:104\u201310."},{"key":"4051_CR39","unstructured":"National Healthcare Security Administration. National Catalogue of Medicines for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance. (2023) [Internet]. 2023 [cited 2024 Apr 1]. Available from: https:\/\/www.mohrss.gov.cn\/xxgk2020\/fdzdgknr\/shbx_4216\/gsbx\/202401\/P020240117600180317106.pdf"},{"key":"4051_CR40","doi-asserted-by":"publisher","first-page":"e056668","DOI":"10.1136\/bmjopen-2021-056668","volume":"12","author":"J Niu","year":"2022","unstructured":"Niu J, Ning L, Zhang Q, Liu Z, Ma Y, Xu X, et al. Health-related quality of life of patients with haemophilia: a cross-sectional survey in the Northeast of China. BMJ Open. 2022;12:e056668.","journal-title":"BMJ Open"},{"key":"4051_CR41","unstructured":"Lulu Liu. Comparison and Influencing Factors of Health State Utility Measures in Hemophilia A Patients [Internet] [Master\u2019s degree]. Shandong University; 2022 [cited 2023 Nov 2]. Available from: https:\/\/kns.cnki.net\/kcms2\/article\/abstract?v=xzY5Ip_ThcnZEpWkBReCdehEm3hGH59XsZIyUgp4iB9PNrf-mCdiJeWAiPacTsvnqCZr9ZvTx4WZzUEyNO6RhsYa1eBfNmIN8M-gbknFJxbZtviTZmgY9Q263i5O_pL__6oy-WjjerCmtz6LvTj-iA==%26uniplatform=NZKPT%26language=CHS"},{"key":"4051_CR42","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.hcr.2024.100007","volume":"1","author":"Y Bai","year":"2025","unstructured":"Bai Y, Liu L, Wang H, Wang J, Shi Z, Feng J, et al. Patient-reported outcome measures in adults with hemophilia: A scoping review. Healthc Rehabilitation. 2025;1:100007.","journal-title":"Healthc Rehabilitation"},{"key":"4051_CR43","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/14737167.2023.2189590","volume":"23","author":"A Zhang","year":"2023","unstructured":"Zhang A, Mao Z, Wang Z, Wu J, Luo N, Wang P. Comparing measurement properties of EQ-5D and SF-6D in East and South-East Asian populations: a scoping review. Expert Rev Pharmacoecon Outcomes Res. 2023;23:449\u201368.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"4051_CR44","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13023-018-0929-9","volume":"13","author":"AO Oladapo","year":"2018","unstructured":"Oladapo AO, Lu M, Walsh S, O\u2019Hara J, Kauf TL. Inhibitor clinical burden of disease: a comparative analysis of the CHESS data. Orphanet J Rare Dis. 2018;13:198.","journal-title":"Orphanet J Rare Dis"},{"key":"4051_CR45","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/bjh.17322","volume":"192","author":"X Dou","year":"2021","unstructured":"Dou X, Liu W, Poon M-C, Zhang X, Wu J, Zeng X, et al. Patients with haemophilia A with inhibitors in china: a National real-world analysis and follow-up. Br J Haematol. 2021;192:900\u20138.","journal-title":"Br J Haematol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04051-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04051-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04051-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:39:17Z","timestamp":1761298757000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-04051-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4051"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04051-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was screened and approved by the Ethics Committee of the Centre for Health Management and Policy Research of Shandong University (No. ECSHCMSDU20200601). All participants gave their informed consent by signing the consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"538"}}